Basic Information
Epclusa
Regulatory Information
EMEA/H/C/004210
Authorised
July 6, 2016
May 26, 2016
22
September 26, 2023
Company Information
Ireland
IDA Business & Technology Park Carrigtohill County Cork T45 DP77
GILEAD SCIENCES IRELAND UC
Drug Classification
Accelerated Assessment
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).
Overview Summary
Epclusa is an antiviral medicine used to treat patients from 3 years of age with chronic (long-term) hepatitis C, an infectious disease that affects the liver, caused by the hepatitis C virus. Hepatitis C virus occurs in several varieties (genotypes), and Epclusa can be used to treat hepatitis C caused by all genotypes of the virus. Epclusa contains the active substances sofosbuvir and velpatasvir.